Literature DB >> 35873890

Efficacy analysis of Cheng's GIRAFFE reconstruction after proximal gastrectomy for adenocarcinoma of esophagogastric junction.

Zhiyuan Xu1, Can Hu1,2, Yanqiang Zhang1, Ling Huang1, Litao Yang1, Jianfa Yu1, Pengfei Yu1, Jiahui Chen1, Yian Du1, Xiangdong Cheng1.   

Abstract

Objective: Reconstruction of the digestive tract for adenocarcinoma of esophagogastric junction (AEG) is in dispute. This study evaluated Cheng's gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's GIRAFFE anastomosis) in laparoscopic/open proximal gastrectomy for Siewert type II AEG, which was performed at Zhejiang Cancer Hospital and the First Affiliated Hospital of Zhejiang Chinese Medical University. Here, we discuss the preliminary results of gastric emptying and anti-reflux.
Methods: From a retrospective database, 74 patients with advanced Siewert type II AEG underwent curative proximal gastrectomy with GIRAFFE anastomosis, and their gastric emptying and anti-reflux outcomes were evaluated by the Reflux Disease Questionnaire (RDQ) score, nuclide gastric emptying, 24-h impedance-pH monitoring and gastroscopy.
Results: Seventy-four patients successfully completed proximal partial gastrectomy with Cheng's GIRAFFE esophagogastric anastomosis. RDQ score six months after the operation was 2.2±2.5. Results of nuclide gastric emptying examinations showed that the gastric half-emptying time was 67.0±21.5 min, the 1-h residual rate was (52.2±7.7)%, the 2-h residual rate was (36.4±5.1)%, and the 3-h residual rate was (28.8±3.6)%; 24-h impedance-pH monitoring revealed that the mean DeMeester score was 5.8±2.9. Reflux esophagitis was observed by gastroscopy in 7 patients six months after surgery. Conclusions: Cheng's GIRAFFE anastomosis is safe and feasible for Siewert type II AEG. © Chinese Journal of Cancer Research. All rights reserved.

Entities:  

Keywords:  Cheng’s GIRAFFE anastomosis; Siewert type II AEG; anti-reflux; proximal gastrectomy

Year:  2022        PMID: 35873890      PMCID: PMC9273578          DOI: 10.21147/j.issn.1000-9604.2022.03.08

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   4.026


  20 in total

Review 1.  Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers.

Authors:  Arnulf H Hölscher; Simon Law
Journal:  Gastric Cancer       Date:  2019-11-06       Impact factor: 7.370

Review 2.  True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends.

Authors:  Tsutomu Kumamoto; Yasunori Kurahashi; Hirotaka Niwa; Yasutaka Nakanishi; Koichi Okumura; Rie Ozawa; Yoshinori Ishida; Hisashi Shinohara
Journal:  Surg Today       Date:  2019-07-05       Impact factor: 2.549

3.  Clinical experience of laparoscopy-assisted proximal gastrectomy with Toupet-like partial fundoplication in early gastric cancer for preventing reflux esophagitis.

Authors:  Shinichi Sakuramoto; Keishi Yamashita; Shiro Kikuchi; Nobue Futawatari; Natsuya Katada; Hiromitsu Moriya; Kazuya Hirai; Masahiko Watanabe
Journal:  J Am Coll Surg       Date:  2009-06-18       Impact factor: 6.113

4.  The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type II and Siewert type III patients.

Authors:  Hironobu Goto; Masanori Tokunaga; Yuichiro Miki; Rie Makuuchi; Norihiko Sugisawa; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masahiro Niihara; Yasuhiro Tsubosa; Masanori Terashima
Journal:  Gastric Cancer       Date:  2014-03-22       Impact factor: 7.370

5.  Comparison of three digestive tract reconstruction methods for the treatment of Siewert II and III adenocarcinoma of esophagogastric junction: a prospective, randomized controlled study.

Authors:  Zhiguo Li; Jianhong Dong; Qingxing Huang; Wanhong Zhang; Kai Tao
Journal:  World J Surg Oncol       Date:  2019-12-06       Impact factor: 2.754

6.  Changing trends of disease burden of gastric cancer in China from 1990 to 2019 and its predictions: Findings from Global Burden of Disease Study.

Authors:  Tongchao Zhang; Hui Chen; Xiaolin Yin; Qiufeng He; Jinyu Man; Xiaorong Yang; Ming Lu
Journal:  Chin J Cancer Res       Date:  2021-02-28       Impact factor: 5.087

7.  Surgical treatment of gastric cancer: Current status and future directions.

Authors:  Jiahui Chen; Zhaode Bu; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

8.  Laparoscopic surgery for gastric cancer: Current status and future direction.

Authors:  So Hyun Kang; Hyung-Ho Kim
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

9.  Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option.

Authors:  Can Hu; Hao-Te Zhu; Zhi-Yuan Xu; Jian-Fa Yu; Yi-An Du; Ling Huang; Peng-Fei Yu; Li-Jing Wang; Xiang-Dong Cheng
Journal:  J Int Med Res       Date:  2018-10-08       Impact factor: 1.671

10.  Proximal Gastrectomy versus Total Gastrectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Comprehensive Analysis of Data from the SEER Registry.

Authors:  Kaixuan Zhu; Yingying Xu; Jiaxin Fu; Farah Abdidahir Mohamud; Zongkui Duan; Siyuan Tan; Zekun Zhao; Ping Chen; Liang Zong
Journal:  Dis Markers       Date:  2019-12-31       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.